Literature DB >> 6474015

Antibodies to lipid A: occurrence in humans.

I Mattsby-Baltzer, C R Alving.   

Abstract

Lipid A, the toxic part of the bacterial endotoxin, is a common antigen for many gram-negative bacteria. Antibodies to lipid A occur naturally in humans; they have been found in 10%-34%, and even up to 73%, of individuals tested, as detected by indirect hemolysis and enzyme-linked immunosorbent assay (ELISA), respectively. Inflammatory bowel diseases (Crohn's disease or ulcerative colitis) cause changes in the level of antibodies to lipid A, as compared with that found in healthy control subjects. Increased levels of antibodies to lipid A are seen in both children and adults with infections due to gram-negative bacteria, such as urinary tract infections (UTI). The highest titers of IgG in serum, as detected by ELISA, have been recorded in patients with development or progression of renal scarring associated with UTI. Since lipid A may play a role in the pathogenesis of renal impairment, the determination of the level of antibodies to lipid A may help in the diagnosis of certain forms of UTI. Possible beneficial roles of antibodies to lipid A during septicemia caused by gram-negative bacteria in humans are still unclear.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6474015     DOI: 10.1093/clinids/6.4.553

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  9 in total

Review 1.  Infectious disease therapy in the 1990s. Where are we heading?

Authors:  M Rozenberg-Arska; M R Visser
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

Review 2.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

3.  Specific detection of Haemophilus influenzae type b lipooligosaccharide by immunoassay.

Authors:  J Mertsola; R S Munford; O Ramilo; X Sáez-Llorens; M M Mustafa; G H McCracken; E J Hansen
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

Review 4.  Prospects for monoclonal antibodies in the diagnosis and treatment of bacterial infections.

Authors:  J Verhoef; R Torensma
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-04       Impact factor: 3.267

5.  A direct enzyme-linked immunosorbent assay (ELISA) for antibodies to enterobacterial Re core glycolipid and lipid A. Results in healthy subjects and in patients infected by gram-negative bacteria.

Authors:  M Nys; P Damas; F Damas; L Joassin; J Demonty
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

6.  Characterization of two different antibody specificities recognizing distinct antigenic determinants in free lipid A of Escherichia coli.

Authors:  L Brade; H Brade
Journal:  Infect Immun       Date:  1985-06       Impact factor: 3.441

7.  Studies of the specificity and cross-reactions of antibodies to lipid A found in juvenile arthritis.

Authors:  J J Miller; L C Olds
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

8.  Serum antibodies against common antigens of bacterial lipopolysaccharides in healthy adults and in patients with multiple myeloma.

Authors:  C Stoll; I Schedel; D Peest
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

9.  Endotoxin neutralization as a biomonitor for inflammatory bowel disease.

Authors:  Keith Champion; Laura Chiu; John Ferbas; Michael Pepe
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.